GO
| HSI1 | 22,841.62 | -453.13 | 229.55B |
| HSCEI1 | 7,690.34 | -145.93 | 94.38B |
| Back Zoom + Zoom - Block Traded | |
|
2026-11-19 16:00:32 Citi released a research report saying that the National Healthcare Security Administration has completed negotiations for the 2026 National Reimbursement Drug List (NRDL). A total of 107 drugs were newly added to the list this year, including 51 innovative drugs from INNOVENT BIO (01801.HK), HUTCHMED (00013.HK), SKB BIO (06990.HK), 3SBIO (01530.HK), ASCENTAGE (06855.HK), JUNSHI BIO (01877.HK), EVEREST MED (01952.HK), CSPC PHARMA (01093.HK), HANSOH PHARMA (03692.HK), SBP GROUP (01177.HK), FOSUN PHARMA (02196.HK) and CMS (00867.HK). Meanwhile, 34 drugs were removed from the list due to reasons including limited clinical value, availability of better alternatives, or insufficient necessary information in drug labels. The new list recorded a net increase of 78 drug specifications, bringing the total number of listed drugs to 3,331, including 1,935 western medicines and 1,396 traditional Chinese medicines. Citi noted that JW THERAP-B (02126.HK)'s CAR-T product relma-cel entered the NRDL at a price of RMB288,600, representing a price cut of 77.6%. The innovative drug catalogue for commercial insurance newly included 12 drugs, including CAR-T therapies. Although post-negotiation drug prices for most products have yet to be disclosed, most pharmaceutical companies contacted by the bank guided that the price cuts were mild and manageable. The new catalogue will take effect from Jan 1, 2027, and the bank will monitor the final tender prices after implementation.(gc/da)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |